menu
    • menu
    [{"orgOrder":0,"company":"EnteroBiotix","sponsor":"Imperial College London","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Microorganism","year":"2022","type":"Partnership","leadProduct":"EBX-102","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"EnteroBiotix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"EnteroBiotix \/ Imperial College London","highestDevelopmentStatusID":"8","companyTruncated":"EnteroBiotix \/ Imperial College London"},{"orgOrder":0,"company":"EnteroBiotix","sponsor":"Thairm Bio","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Series A Financing","leadProduct":"EBX-101","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"EnteroBiotix","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"EnteroBiotix \/ Thairm Bio","highestDevelopmentStatusID":"1","companyTruncated":"EnteroBiotix \/ Thairm Bio"},{"orgOrder":0,"company":"EnteroBiotix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Probiotic","year":"2024","type":"Inapplicable","leadProduct":"EBX-102-02","moa":"Gut microbiome","graph1":"Gastroenterology","graph2":"Phase II","graph3":"EnteroBiotix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"EnteroBiotix \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"EnteroBiotix \/ Inapplicable"},{"orgOrder":0,"company":"EnteroBiotix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Probiotic","year":"2024","type":"Inapplicable","leadProduct":"EBX-102-02","moa":"Gut microbiome","graph1":"Gastroenterology","graph2":"Phase II","graph3":"EnteroBiotix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"EnteroBiotix \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"EnteroBiotix \/ Inapplicable"},{"orgOrder":0,"company":"EnteroBiotix","sponsor":"Thairm Bio","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Probiotic","year":"2024","type":"Financing","leadProduct":"EBX-102-02","moa":"Gut microbiome","graph1":"Gastroenterology","graph2":"Phase II","graph3":"EnteroBiotix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"EnteroBiotix \/ Thairm Bio","highestDevelopmentStatusID":"8","companyTruncated":"EnteroBiotix \/ Thairm Bio"},{"orgOrder":0,"company":"EnteroBiotix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Probiotic","year":"2025","type":"Inapplicable","leadProduct":"EBX-102-02","moa":"Gut microbiome","graph1":"Gastroenterology","graph2":"Phase II","graph3":"EnteroBiotix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"EnteroBiotix \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"EnteroBiotix \/ Inapplicable"},{"orgOrder":0,"company":"EnteroBiotix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"UNITED KINGDOM","productType":"Microorganism","year":"2024","type":"Inapplicable","leadProduct":"EBX-102","moa":"Undisclosed","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"EnteroBiotix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"EnteroBiotix \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"EnteroBiotix \/ Inapplicable"},{"orgOrder":0,"company":"EnteroBiotix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"UNITED KINGDOM","productType":"Microorganism","year":"2023","type":"Inapplicable","leadProduct":"EBX-102","moa":"Undisclosed","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"EnteroBiotix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"EnteroBiotix \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"EnteroBiotix \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals by EnteroBiotix

    Menu

    EnteroBiotix

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            EnteroBiotix

                            United Kingdom arrow
                            Cophex
                            Not Confirmed

                            EnteroBiotix

                            United Kingdom arrow
                            Cophex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : EBX-102-02

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            EnteroBiotix Reports Positive Phase 2a Results for EBX-102-02 in IBS

                            Details : EBX-102-02, the company’s next-generation full-spectrum microbiome product, currently under clinical trials in adults with irritable bowel syndrome with constipation (IBS-C).

                            Product Name : EBX-102-02

                            Product Type : Probiotic

                            Upfront Cash : Inapplicable

                            March 18, 2025

                            Lead Product(s) : EBX-102-02

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            EnteroBiotix

                            United Kingdom arrow
                            Cophex
                            Not Confirmed

                            EnteroBiotix

                            United Kingdom arrow
                            Cophex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : EBX-102-02

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            EnteroBiotix Completes Phase 2 Study Recruitment of EBX-102-02 in Irritable Bowel Syndrome

                            Details : EBX-102-02 is a next-generation, full-spectrum drug candidate that restore and fortify the microbiome. It is being evaluated for irritable bowel syndrome.

                            Product Name : EBX-102-02

                            Product Type : Probiotic

                            Upfront Cash : Inapplicable

                            November 18, 2024

                            Lead Product(s) : EBX-102-02

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            EnteroBiotix

                            United Kingdom arrow
                            Cophex
                            Not Confirmed

                            EnteroBiotix

                            United Kingdom arrow
                            Cophex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : EBX-102

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            EnteroBiotix Announces Positive Ph1b Clinical Results of EBX-102 in Liver Cirrhosis

                            Details : EBX-102 is a next-generation, full-spectrum drug candidate that contains highly diverse microbial ecosystems that restore and fortify the microbiome. It is being evaluated for Liver cirrhosis.

                            Product Name : EBX-102

                            Product Type : Microorganism

                            Upfront Cash : Inapplicable

                            November 11, 2024

                            Lead Product(s) : EBX-102

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            EnteroBiotix

                            United Kingdom arrow
                            Cophex
                            Not Confirmed

                            EnteroBiotix

                            United Kingdom arrow
                            Cophex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : EBX-102-02

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase II

                            Sponsor : Thairm Bio

                            Deal Size : $34.0 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            EnteroBiotix Completes £27m Financing Round to Advance Clinical Trials

                            Details : The net proceeds will advance EBX’s lead candidate, EBX-102-02, a next-generation drug with diverse microbial ecosystems, through a Phase 2 trial in Irritable Bowel Syndrome.

                            Product Name : EBX-102-02

                            Product Type : Probiotic

                            Upfront Cash : Undisclosed

                            April 04, 2024

                            Lead Product(s) : EBX-102-02

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase II

                            Sponsor : Thairm Bio

                            Deal Size : $34.0 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            EnteroBiotix

                            United Kingdom arrow
                            Cophex
                            Not Confirmed

                            EnteroBiotix

                            United Kingdom arrow
                            Cophex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : EBX-102-02

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            EnteroBiotix Initiates Phase 2 Study of EBX-102-02 for Irritable Bowel Syndrome

                            Details : EBX-102-02 is a next-gen drug candidate with diverse microbial ecosystems, evaluated for restoring the microbiome in patients with irritable bowel syndrome.

                            Product Name : EBX-102-02

                            Product Type : Probiotic

                            Upfront Cash : Inapplicable

                            March 04, 2024

                            Lead Product(s) : EBX-102-02

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            EnteroBiotix

                            United Kingdom arrow
                            Cophex
                            Not Confirmed

                            EnteroBiotix

                            United Kingdom arrow
                            Cophex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : EBX-102

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            EnteroBiotix Initiates Phase 2 Study of Microbiome Drug EBX-102 In Liver Cirrhosis and Hepatic Encephalopathy

                            Details : EBX-102 is an oral capsule that contains diverse full-spectrum microbial ecosystems that are intended to restore microbial ecology and act in concert to target multiple key disease pathways. It is being developed for in liver cirrhosis and hepatic enceph...

                            Product Name : EBX-102

                            Product Type : Microorganism

                            Upfront Cash : Inapplicable

                            March 28, 2023

                            Lead Product(s) : EBX-102

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            EnteroBiotix

                            United Kingdom arrow
                            Cophex
                            Not Confirmed

                            EnteroBiotix

                            United Kingdom arrow
                            Cophex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : EBX-102

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Imperial College London

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            EnteroBiotix Partners With Imperial College London To Develop Microbiome Therapeutics

                            Details : EBX and Imperial are partnering to manage a Phase II, a investigator initiated trial, to evaluate how EBX-102 impacts on outcomes of bone marrow transplant patients with blood cancer.

                            Product Name : EBX-102

                            Product Type : Microorganism

                            Upfront Cash : Undisclosed

                            October 11, 2022

                            Lead Product(s) : EBX-102

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Imperial College London

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            EnteroBiotix

                            United Kingdom arrow
                            Cophex
                            Not Confirmed

                            EnteroBiotix

                            United Kingdom arrow
                            Cophex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : EBX-101

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Undisclosed

                            Sponsor : Thairm Bio

                            Deal Size : $21.5 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            EnteroBiotix Raises over $21m in Series A Financing to Advance its Microbiome Drug Pipeline

                            Details : The proceeds will be used to further advance the company's microbiome drug pipeline and EBX-101 development and manufacturing capabilities.

                            Product Name : EBX-101

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            July 09, 2021

                            Lead Product(s) : EBX-101

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Undisclosed

                            Sponsor : Thairm Bio

                            Deal Size : $21.5 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth